Retrospective real world treatment patterns and clinical outcomes with palbociclib combination therapy in patients with HR+/HER2- advanced and metastatic breast cancer
Latest Information Update: 14 Feb 2019
Price :
$35 *
At a glance
- Drugs Palbociclib (Primary) ; Aromatase inhibitors; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 14 Feb 2019 New trial record